Cyclosporine for Treatment of Early Type I Diabetes: Preliminary Results

Abstract

To the Editor: We wish to report our early observations from a feasibility study of cyclosporine therapy in human Type I diabetes. The superiority of cyclosporine has been demonstrated,^{1 , 2} and the drug prevents diabetes in the relevant BB rat model.³ In considering the theoretical benefit of immunosuppression,⁴ the risks associated with cyclosporine (lymphoma 5 were weighed against the well-documented morbidity and mortality of Type I diabetes. Ethical approval for the study was obtained, and 15 of 30 eligible subjects between the ages of 10 and 30 years gave informed consent.Seven patients with . . .